Another field of interest for Dr. Boutaud is the study of acetaminophen mechanism of action. He characterized the molecular mechanism by which acetaminophen inhibits the cyclooxygenases. His first publication in this field demonstrated that acetaminophen works not as an inhibitor of the cyclooxygenase site, as do most of the other NSAIDs, but as a reductant of the heme in the peroxidase site [12] . This discovery was key for understanding the pharmacological profile of this drug and initiated a series of papers demonstrated that the peroxide tone in the environment of the enzymes also affected how salicylate and aspirin work [13] . This work culminated in showing that in metabolic syndrome patients with diabetes, a condition with high oxidative stress, aspirin was much less effective in inhibiting platelet function than in subjects with lower oxidative stress [14] . His work on myoglobin was the basis for showing that acetaminophen protects the kidney from injury following rhabdomyolysis in vivo [15] . Following this line of thoughts, he has also shown that cytochrome c-catalyzed oxidation of mitochondrial cardiolipin is inhibited by acetaminophen [16] . This work led to the concept that hemeprotein reductants could be used in vivo to treat conditions associated with preoxidase-dependent lipid peroxidation, such as rhabdomyolysis, malaria, sickle cell disease, etc. For this reason, Dr. Boutaud has developed analogs of acetaminophen that are more efficacious and less toxic [17] . This work also led Dr. Boutaud to make the seminal discovery that cardiolipin fatty acid composition regulates electron entry in the respiratory chain in the mitochondria [18] .
He characterized that the inhibitory phenotype was determined by the PGE 2 receptor subtype 4 and that the potentiating phenotype was determined by the PGE 2 receptor subtype 3 [19, 20] .
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